Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double‐blind, placebo‐controlled, phase 3 trial ( SYNCHRONIZE ™‐1)
Open Access
- 4 November 2025
- journal article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (1) , 337-346
Abstract
Aims: Survodutide, a novel glucagon receptor and glucagon‐like peptide‐1 (GLP‐1) receptor dual agonist, elicited significant weight loss in a phase 2 trial in individuals with obesity without type 2 diabetes (T2D). Two multinational phase 3 trials are investigating survodutide for obesity management in individuals with or without T2D. We report the baseline characteristics of participants in the SYNCHRONIZE‐1 trial in adults with obesity without T2D ( ClinicalTrials.gov : NCT06066515). Materials and methods: Participants aged ≥18 years with BMI ≥30 or ≥27 kg/m 2 with ≥1 obesity complication without T2D were randomized 1:1:1 to double‐blind, once‐weekly, subcutaneous injections of survodutide (up‐titrated to 3.6 or 6.0 mg) or placebo for 76 weeks. The primary endpoints are percent body weight change and achievement of body weight reduction ≥5% from baseline to Week 76. Efficacy and safety analyses will include all randomized and treated participants. Results: At baseline, participants ( n = 725 from 14 countries) had a mean age of 47.1 years, BMI 37.9 kg/m 2 , and waist circumference 115.2 cm. Most participants (59.4%) were female; 47.3% were from North America, 21.0% from Europe, and 20.0% from East Asia. Obesity complications included hypertension (40.0%), dyslipidaemia (33.7%), and prediabetes (30.2%). Mean haemoglobin A1c was 5.5%, estimated glomerular filtration rate 93.0 mL/min/1.73 m 2 , systolic/diastolic blood pressure 127.0/82.7 mmHg, and low‐density lipoprotein cholesterol 116.4 mg/dL; 21.8% were taking lipid‐lowering drugs. Conclusions: SYNCHRONIZE‐1 will determine the efficacy, safety, and tolerability of survodutide, a glucagon receptor/GLP‐1 receptor dual agonist, for weight loss in a representative cohort of people with obesity without T2D.Keywords
Funding Information
- Boehringer Ingelheim
This publication has 48 references indexed in Scilit:
- Managing Adverse Effects of Incretin-Based Medications for ObesityJAMA, 2025
- Development and validation of an eating behavior patient‐reported outcome measure in people living with obesity or overweightObesity, 2025
- A GLP1R gene variant and sex influence the response to semaglutide treatment in patients with severe obesityObesity, 2025
- Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™‐1 and ‐2)Obesity, 2024
- Survodutide for the Treatment of ObesityJACC: Heart Failure, 2024
- Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection FractionJACC, 2024
- BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacyMolecular Metabolism, 2022
- Obesity definition, diagnosis, bias, standard operating procedures (SOPs), and telehealth: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022Obesity Pillars, 2022
- GLP-1 physiology informs the pharmacotherapy of obesityMolecular Metabolism, 2021
- 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in AdultsJACC, 2014